Navigation Links
ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Date:8/19/2008

ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the company to commercialize human mesenchymal cells developed at the University of Georgia.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

Under the terms of the agreement, ArunA has acquired an exclusive worldwide license to develop and commercialize human mesenchymal cells (hMSC(TM)) derived from human embryonic stem cells, a product never before available. ArunA will offer the academic and industrial research communities access to a highly uniform population of human mesenchymal cells grown as adherent monolayer cultures in multiple turn-key kit formats. The hMSC kits will provide a physiologically relevant and genetically stable source of research material for use in a broad range of life science research applications such as: developmental pathway studies, disease modeling, in vitro toxicology, compound screening and humanized animal models.

"ArunA's proprietary adherent monolayer culture technology creates millions of highly uniform cells. These unique cells provide researchers with new enabling tools that can have a measurable impact on the advancement of drug discovery," says ArunA Biomedical President and Chief Executive Officer, William Sharp. "We are targeting an early first quarter 2009 launch of ArunA's first hMSC kit."

According to Robert Nerem, the Parker H. Petit Distinguished Chair for Engineering in Medicine at the Georgia Institute of Technology, "One of the most important uses of human embryonic stem cells will be in the generation of uniform populations of adult stem cells and progenitor cells. It is thus exciting that ArunA Biomedical will be able to provide uniform cell populations of human mesenchymal cells in kit form. This not only will be of value to bench scientists, but also in advancement toward clinical therapies."

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.
http://www.arunabiomedical.com


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
4. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
5. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
6. HIPAA Privacy Rule Impedes Biomedical Research
7. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
8. Environmental Tectonics Corporations BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers
9. The NCIIA Recognizes Collegiate Biomedical Engineering Innovations
10. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
11. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):